VAERS reports by lot

Pfizer COVID-19 lot 30125BA: VAERS reports

107 VAERS reports list lot 30125BA as a Pfizer COVID-19 vaccine, received between 2021-09-28 and 2024-08-28. Data: VAERS public files through 31 December 2024 (site extract 2026-07-04).

Read this first. VAERS accepts reports from anyone, and a report does not establish that the vaccine caused the event. A lot's report count mostly reflects how many doses it contained, when it was used and who received it; no administered-dose counts are published for this lot, so counts are not rates and cannot rank lots against each other. Lot numbers in VAERS reports are typed by reporters and are sometimes wrong.
107
Reports
27%
Marked serious
2
With a death outcome
23
Months with reports

Symptom categories in these reports

A report can mention several categories, so the counts add up to more than the number of reports.

CategoryCount%
General / Systemic (non-local)7719%
Cardiac / Cardiovascular7017%
Gastrointestinal6716%
Neurological5513%
Musculoskeletal359%
Injection-site / Local reaction328%
Respiratory297%
Dermatological (non-injection-site)113%
Allergic / Anaphylactic92%
Psychiatric / Neuropsychiatric92%
Autoimmune / Immune-mediated72%
Thrombotic / Hematological51%
Reproductive / Menstrual41%

Where reports came from

U.S. state of the reporter, where given (top 12).

Michigan12
Pennsylvania11
Kentucky10
North Carolina8
New York8
Texas6
Illinois6
Ohio5
Wisconsin5
Maryland4
Georgia3
South Carolina3

Reports by month received

2021-096
2021-1031
2021-1115
2021-128
2022-017
2022-026
2022-037
2022-043
2022-056
2022-073
2022-081
2022-091
2022-101
2022-121
2023-011
2023-021
2023-031
2023-052
2023-111
2024-011
2024-041
2024-061
2024-082

Products recorded with this lot

Manufacturer and product as reported in VAERS. Reports listing the lot under more than one product are counted once.

Related

Source: VAERS public data (CDC/FDA), grouped by manufacturer and lot by the Open Source Medicine Foundation; extract 2026-07-04 16:35 UTC. Not medical advice. Report errors via contact.